Rapport Therapeutics Stock (NASDAQ: RAPP)

Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

KYMR

RAPP

VERA

The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical

Analysts Can&#39;t Get Enough of These Little-Known Biopharma Stocks

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

Intraday Update

Markets

Movers

Trading Ideas

ADMA

CGON

Hims & Hers Health, Inc. Class A Common Stock

HIMS

PLUG

PONY

PTON

SABR

SMMT

URGN

VEON

WOLF

Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday

Stock Movers

News

Pre-Market Outlook

MLNK

MVST

NCMI

NCNO

NMAX

TSLA

nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics Inc

Health Care

Press Releases

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Management

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Earnings

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

Rapport Therapeutics to Host 2025 Investor and Analyst Day

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Evolus

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Maze Therapeutics

MBX Biosciences

Nektar Therapeutics

Nuvation Bio

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Tilray Brands

Trevi Therapeutics

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

JMP Securities

Jones Trading

Stifel

Jefferies

Comments

Rapport Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell